Transdermal/Dermal Drug Delivery System

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 7998

Special Issue Editor


E-Mail Website
Guest Editor
Department of Pharmaceutics, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China
Interests: transdermal/dermal drug delivery; topical delivery; skin barrier; follicular delivery; nanocarriers; microneedles; skin diseases

Special Issue Information

Dear Colleagues,

Transdermal/dermal drug delivery is developed for systemic/topical disease treatment, which delivers drugs through the skin or directly to the skin lesions to avoid gastrointestinal tract enzymatic digestion and liver first-pass metabolism, reduce gastrointestinal tract irritation, and improve patient compliance. It is one of the most favorable methods among novel drug delivery systems because it has been widely used to treat systemic diseases and topical diseases. Moreover, skin diseases in topical diseases are the fourth leading cause of nonfatal and chronic disease, such as bacterial and fungal infections, psoriasis, dermatitis, eczema, vitiligo, oxidative damage, aging, alopecia, and skin cancer.

However, the stratum corenum (SC) in the upmost layer of the skin is a barrier against pathogens, but also drugs or drug-carrier diffusion. Therefore, to safely overcome the SC barrier and to efficiently deliver drugs across the SC still remain as challenges. Many strategies are designed to solve the issue including physical, chemical, and pharmaceutical methods. Among them, nanocarrier- or microneedle- mediated transdermal delivery systems are attractive advanced technologies. Nanocarrier-based transdermal delivery systems include lipid-based (nanoemulsions, microemulsions, solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs)), and vesicular carriers (non-deformable, such as liposomes, niosomes, emulsomes and cerosomes, and deformable, such as transfersomes, ethosomes, transethosomes, and penetration enhancer vesicles). They can encapsulate drugs, promote skin penetration with controlled or on-demand drug release properties, and improve treatment outcomes. Microneedles can pierce the skin and deliver drugs to the dermis in a painless and minimum-invasive manner, and they combine the benefits of both topical-transdermal and injectable drug administration approaches. Furthermore, the combination of nanocarriers with microneedles can formulate a more advanced transdermal/dermal delivery system with integrated advantages.

The present Special Issue serves as an overview of current research on transdermal/dermal drug delivery systems, as strategies and formulative approaches to treat systemic and topical diseases, the overcoming SC barrier and the enhanced transdermal/dermal delivery or permeation of drugs.

Prof. Dr. Yuehong Xu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • transdermal/dermal drug delivery
  • topical delivery
  • skin barrier
  • follicular delivery
  • nanocarriers
  • microneedles
  • skin diseases
  • permeation enhancing

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 1179 KiB  
Article
Immobilized Keratin HPLC Stationary Phase—A Forgotten Model of Transdermal Absorption: To What Molecular and Biological Properties Is It Relevant?
by Anna Weronika Sobańska and Elżbieta Brzezińska
Pharmaceutics 2023, 15(4), 1172; https://doi.org/10.3390/pharmaceutics15041172 - 7 Apr 2023
Viewed by 1330
Abstract
Chromatographic retention data collected on immobilized keratin (KER) or immobilized artificial membrane (IAM) stationary phases were used to predict skin permeability coefficient (log Kp) and bioconcentration factor (log BCF) of structurally unrelated compounds. Models of both properties contained, apart from [...] Read more.
Chromatographic retention data collected on immobilized keratin (KER) or immobilized artificial membrane (IAM) stationary phases were used to predict skin permeability coefficient (log Kp) and bioconcentration factor (log BCF) of structurally unrelated compounds. Models of both properties contained, apart from chromatographic descriptors, calculated physico-chemical parameters. The log Kp model, containing keratin-based retention factor, has slightly better statistical parameters and is in a better agreement with experimental log Kp data than the model derived from IAM chromatography; both models are applicable primarily to non-ionized compounds.Based on the multiple linear regression (MLR) analyses conducted in this study, it was concluded that immobilized keratin chromatographic support is a moderately useful tool for skin permeability assessment.However, chromatography on immobilized keratin may also be of use for a different purpose—in studies of compounds’ bioconcentration in aquatic organisms. Full article
(This article belongs to the Special Issue Transdermal/Dermal Drug Delivery System)
Show Figures

Figure 1

Review

Jump to: Research

23 pages, 1644 KiB  
Review
Advance and Challenges in the Treatment of Skin Diseases with the Transdermal Drug Delivery System
by Tingting Cheng, Zongguang Tai, Min Shen, Ying Li, Junxia Yu, Jiandong Wang, Quangang Zhu and Zhongjian Chen
Pharmaceutics 2023, 15(8), 2165; https://doi.org/10.3390/pharmaceutics15082165 - 21 Aug 2023
Cited by 23 | Viewed by 6134
Abstract
Skin diseases are among the most prevalent non-fatal conditions worldwide. The transdermal drug delivery system (TDDS) has emerged as a promising approach for treating skin diseases, owing to its numerous advantages such as high bioavailability, low systemic toxicity, and improved patient compliance. However, [...] Read more.
Skin diseases are among the most prevalent non-fatal conditions worldwide. The transdermal drug delivery system (TDDS) has emerged as a promising approach for treating skin diseases, owing to its numerous advantages such as high bioavailability, low systemic toxicity, and improved patient compliance. However, the effectiveness of the TDDS is hindered by several factors, including the barrier properties of the stratum corneum, the nature of the drug and carrier, and delivery conditions. In this paper, we provide an overview of the development of the TDDS from first-generation to fourth-generation systems, highlighting the characteristics of each carrier in terms of mechanism composition, penetration method, mechanism of action, and recent preclinical studies. We further investigated the significant challenges encountered in the development of the TDDS and the crucial significance of clinical trials. Full article
(This article belongs to the Special Issue Transdermal/Dermal Drug Delivery System)
Show Figures

Graphical abstract

Back to TopTop